Biologic therapies in paediatric severe asthma

J. Paton (Glasgow, United Kingdom)

Source: ERS webinar 2020: Biologic therapies in paediatric severe asthma
Number: 0
Disease area: Airway diseases, Paediatric lung diseases

Slide presentationWebcast

Rating: 4
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Paton (Glasgow, United Kingdom). Biologic therapies in paediatric severe asthma. ERS webinar 2020: Biologic therapies in paediatric severe asthma

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy
Source: Eur Respir Rev 2007; 16: 73-77
Year: 2007

Combination asthma medication and healthcare use in severe or difficult-to-treat asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 131s
Year: 2004

The use of omalizumab in the management of severe chronic paediatric asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008

Immunotherapy in severe asthma
Source: ERS webinar 2021: Immunotherapy in severe asthma
Year: 2021

Pharmacological strategies for self-management of asthma exacerbations
Source: Eur Respir J 2006; 28: 182-199
Year: 2006

Asthma in pre-schoolers: difficult to treat
Source: Annual Congress 2005 - Asthma in the preschool child
Year: 2005

Systematic assessment of difficult-to-treat asthma
Source: Eur Respir J 2003; 22: 478-483
Year: 2003

Treatment of severe childhood asthma: what’s the evidence?
Source: Annual Congress 2005 - Difficult asthma in children
Year: 2005

Nonadherence in the era of severe asthma biologics and thermoplasty
Source: Eur Respir J, 51 (4) 1701836; 10.1183/13993003.01836-2017
Year: 2018

Evaluation of the difficult-to-treat severe asthma patient in the clinic
Source: Eur Respir Mon 2011; 51: 16-27
Year: 2011

Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021

Which patients should be treated with anti-IgE?
Source: Eur Respir Rev 2007; 16: 85-87
Year: 2007

Real-life long-term omalizumab therapy in children with severe allergic asthma
Source: Eur Respir J 2015; 46: 856-859
Year: 2015

Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD
Source: Annual Congress 2006 - COPD therapy
Year: 2006

Treatment of asthma the current European perspective
Source: Annual Congress 2006 - Childhood asthma therapy: where we are now and where we need to go
Year: 2006

New treatments in severe paediatric asthma
Source: International Congress 2017 – PG7 Paediatric asthma
Year: 2017

Are current treatment recommendations suited to elderly patients with asthma or COPD?
Source: Eur Respir Mon; 2009: 43: 267–285
Year: 2009

What is new in paediatric asthma?
Source: Annual Congress 2006 - Paediatric year in review
Year: 2006

The new approaches to the oral corticosteroid dosage decrease in patients with severe steroid-resistant bronchial asthma
Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population
Year: 2005